User: Guest  Login
Document type:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
Author(s):
Escudier, B; Roigas, J; Gillessen, S; Harmenberg, U; Srinivas, S; Mulder, SF; Fountzilas, G; Peschel, C; Flodgren, P; Maneval, EC; Chen, I; Vogelzang, NJ
Title:
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Abstract:
PURPOSE: Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen. PATIENTS AND METHODS: Eligibility criteria included histologically proven mRCC with measurable disease, failure of one prior cytokine regimen, and good performance status. Patients were randomly assi...     »
Journal title abbreviation:
J Clin Oncol
Year:
2009
Journal volume:
27
Journal issue:
25
Pages contribution:
4068-75
Language:
eng
Fulltext / DOI:
doi:10.1200/JCO.2008.20.5476
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/19652072
Print-ISSN:
0732-183X
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX